Background: Oxidant stress contributes to the pathogenesis of multiple conditions and can be assessed by measuring plasma F 2 -isoprostane concentrations. We hypothesized that oxidant stress is associated with plasma homocysteine concentration and risk factors for atherosclerosis in HIVinfected women. Methods: We measured plasma Oxidant stress, characterized by release of free radicals that damage tissue, is thought to contribute to the ageing process and the pathogenesis of many diseases, including atherosclerosis, cancer, diabetes and neurodegenerative disorders [1] [2] [3] [4] [5] . Measurement of plasma F 2 -isoprostanes, which are prostaglandin-like substances produced by free radical-catalyzed peroxidation of arachidonic acid, has emerged as an accurate and reproducible way to assess oxidant stress in vivo [6] .
Oxidant stress, characterized by release of free radicals that damage tissue, is thought to contribute to the ageing process and the pathogenesis of many diseases, including atherosclerosis, cancer, diabetes and neurodegenerative disorders [1] [2] [3] [4] [5] . Measurement of plasma F 2 -isoprostanes, which are prostaglandin-like substances produced by free radical-catalyzed peroxidation of arachidonic acid, has emerged as an accurate and reproducible way to assess oxidant stress in vivo [6] .
The relationship of oxidant stress to complications of HIV disease and antiretroviral therapy, including mitochondrial toxicities and metabolic complications, is uncertain. McComsey and Morrow [7] found that plasma F 2 -isoprostane levels were higher in HIV-infected patients who had clinically apparent lipoatrophy compared with those without lipoatrophy. In addition, all four patients in their study with symptomatic hyperlactataemia/lactic acidosis had increased F 2 -isoprostane levels relative to those with asymptomatic sustained hyperlactataemia, who did not differ from patients with normal lactates [7] . By contrast, Hulgan et al. [8] found no association between F 2 -isoprostane levels and nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Although F 2 -isoprostanes have been shown to correlate with subclinical atherosclerosis in young healthy individuals [9] , data on the relationship between oxidant stress and factors associated with atherosclerotic risk in HIV-infected patients are lacking.
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Introduction
We hypothesized that greater oxidant stress would be associated with higher levels of homocysteine. The rationale for this hypothesis is that homocysteine, a thiol-containing amino acid, generates free radicals when it is oxidized, primarily via auto-oxidation [10, 11] . This relationship of homocysteine to oxidant stress is one potential mechanism by which homocysteine increases might contribute to atherosclerosis [1, 12] . Specifically, homocysteine might contribute to oxidation of low-density lipoprotein (LDL) cholesterol and to lipid peroxidation, the latter which might be assessed by assaying circulating F 2 -isoprostanes. To study this, we measured plasma F 2 -isoprostanes and homocysteine cross-sectionally in the Bronx (NY, USA) site of the Women's Interagency HIV Study (WIHS), and assessed their relationships to other metabolic parameters.
Methods
The WIHS is a prospective cohort study that has enrolled 3,772 primarily minority women with or at high risk of HIV infection at six urban sites in the United States [13] . The Bronx site enrolled 537 women beginning in 1994 with an additional 233 women enrolled in 2001. At baseline and at each follow-up visit, detailed information was collected on demographics, HIV-related risk behaviour, antiretroviral therapy, anthropometric data, comorbidities, and lifestyle and medication history. Women were asked specifically whether they had taken any complementary or alternative medications, including nutritional supplements, vitamins or minerals since their last study visit, and the names of any such products were recorded. For this study, antioxidant vitamin or mineral use was defined dichotomously (yes/no) as selfreported use of a multivitamin/mineral, zinc, vitamins A, C or E, and/or b-carotene since the last study visit. Informed consent was obtained from all patients and human experimentation guidelines of the US Department of Health and Human Services and those of the authors' institutions were followed in the conduct of this research.
We conducted a cross-sectional study at a recent follow-up visit (visit 24; April-September 2006) in the Bronx WIHS site. Currently enrolled HIV-infected women who were still under active follow-up were included in the present study. The only exclusion criterion was acute illness at the time of the visit as determined by the interviewer at the WIHS site. Blood samples collected in tubes containing EDTA anticoagulant were immediately placed on ice and plasma was separated within 1 h and stored at -70°C.
Plasma levels of 15-F 2 -isoprostane (8-iso-prostaglandin F 2 α) were assayed by gas chromatography/negative ion chemical ionization mass spectrophotometry [6] .
The intraday variability of this assay is <10% and the mean ±sd level of F 2 -isoprostanes in healthy volunteers is 35 ±6 pg/ml [6] . The upper limit of normal of plasma F 2 -isoprostanes in healthy adults is considered to be 41 pg/ml. Homocysteine was assayed by fluorescence polarization immunoassay (Quest Diagnostics, Baltimore, MD, USA). The interassay coefficient of variation for this assay is 8.8%. In order to remove skewness, we used natural log F 2 -isoprostane in most analyses. High sensitivity C-reactive protein (hsCRP) was measured at visits 19 or 20 (approximately 2-2.5 years prior to the time of F 2 -isoprostane measurement) and 20 or 21 (approximately 1.5-2 years prior to the time of F 2 -isoprostane measurement). The mean of both measurements, which was natural log transformed first to remove skewness, was used.
Homeostasis model assessment-insulin resistance (HOMA-IR) [14] was calculated from fasting insulin and glucose values tested within 1 year of the F 2 -isoprostane blood collection using the formula: fasting serum insulin (µU/ml) × fasting plasma glucose (mg/ dl)/405. Hepatitis C virus (HCV) viraemia at entry into the WIHS cohort was assessed by either the COBAS ® Amplicor Monitor 2.0 or the COBAS ® Taqman ® assays (both from Roche Diagnostics, Branchburg, NJ, USA) as previously described [15] . FIB-4, a non-invasive marker of hepatic fibrosis developed for HCV-HIVcoinfected patients [16] , was calculated in HIV-HCVcoinfected women as: age (years) × aspartate aminotransferase (AST)/platelet count (10 9 /l) × alanine aminotransferase (ALT) 1/2 .
Statistical analyses
Data were descriptively analysed using plots, histograms, means, medians, sd, skewness and kurtosis to identify erroneous values, outliers and optimal transformations. Because of large skewness in the original variables, F 2 -isoprostane, hsCRP, fasting glucose concentrations and HOMA-IR were natural log transformed. Continuous variables were summarized in this paper by means ±sd. Because of the presence of three extreme outliers, serum creatinine values >2.0 mg/ dl were set to missing. Associations between log F 2 -isoprostane concentration as a continuous variable and other variables of interest were assessed by univariate and multivariate linear regression modelling, the latter using forward stepwise selection of covariates with a P-value of <0.10 to enter or leave the model. Only covariates with P-values of <0.10 in univariate analyses were considered in multivariate analyses. Regression results and 95% confidence intervals are expressed as relative (percentage) change in F 2 -isoprostane concentration associated with a given change in the predictor, calculated as 100
, where b is the regression coefficient from the model with log F 2 -isoprostane concentration as the outcome. Statistical analyses were performed using SAS version 9.1 software (SAS Institute Inc., Cary, NC, USA). Table 1 summarizes the demographic and clinical characteristics of the 249 HIV-infected women enrolled in this study at the time of the F 2 -isoprostane blood draw. The majority of women had prior clinical diagnosis of AIDS, although the mean ±sd current CD4 + T-cell count was 485 ±326 cells/mm 3 and 53% had HIV RNA levels below the level of quantification (<80 copies/ml). The prevalence of diabetes was 20%, and 28% of women were actively infected with HCV on the basis of circulating HCV RNA.
Results
The mean ±sd log plasma F 2 -isoprostane level was 4.11 ±0.53 log pg/ml, and 195 (78.3%) women had levels ≥3.71 log pg/ml (41 pg/ml; one sd above the mean level reported in healthy volunteers). Plasma F 2 -isoprostane concentration was correlated with plasma homocysteine concentration (r=0.30, P<0.0001; Figure 1 ).
In univariate linear regression with log transformed F 2 -isoprostane concentrations as the outcome (Table 2) , the strongest associations (all at P<0.0001) were observed with waist circumference, presence of HCV viraemia and plasma homocysteine concentration. For example, on a logarithmic scale, a woman who had HCV viraemia had 40.4% higher F 2 -isoprostane concentrations than did a woman without HCV viraemia. F 2 -isoprostane was also positively associated with older age, current smoking, and higher weight, body mass index, systolic blood pressure, diastolic blood pressure, log insulin level, AST and ALT. Log F 2 -isoprostane concentrations were inversely associated with use of antioxidant vitamins or minerals. There were trends for positive associations between log F 2 -isoprostane concentration and log HOMA-IR, and negative associations between log F 2 -isoprostane concentration and CD4 + T-cell percentage (CD4%) and any use of nevirapine. Log F 2 -isoprostane concentrations were not associated with the log hsCRP measurements obtained approximately 2 years previously.
In the final forward stepwise multivariate linear regression model (Table 2) -1) , where b is the regression coefficient (or corresponding lower or upper confidence limit for this coefficient) using log transformed F 2 -isoprostane as the outcome. c FIB-4 [16] was calculated on 68 of 70 women with hepatitis C viraemia, and was not evaluated in multivariate analyses. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; cART, combination antiretroviral therapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HOMA-IR, homeostasis model assessment-insulin resistance; hsCRP, high sensitivity C-reactive protein; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
circumference, homocysteine concentration and serum AST level were all positively associated with log F 2 -isoprostane concentration, whereas CD4% was inversely associated in this multivariate model. We also constructed a separate model that included these covariates selected by forward stepwise regression and also current smoking and age (forced into the model). In this model, age and current smoking were not statistically significant (P=0.37 and 0.22, respectively), and adjusting for these variables had minimal effect on the magnitude of the b coefficients and statistical significance of the other covariates (data not shown).
To explore the association between HCV infection and F 2 -isoprostane concentrations further, we assessed the association between degree of hepatic fibrosis estimated by FIB-4 and plasma F 2 -isoprostanes among the 68 of 70 women with HCV viraemia for whom FIB-4 could be calculated. Their mean ±sd FIB-4 value was 2.13 ±1.64. In a univariate linear regression model, F 2 -isoprostane concentrations increased by 9.05% for each unit increase in FIB-4 score (P=0.049).
Discussion
In this cross-sectional study, we found that plasma F 2 -isoprostane concentrations, an in vivo marker of oxidant stress, were positively associated with plasma homocysteine concentrations, in accordance with our primary hypothesis. We also found positive associations between this measure of oxidant stress and several metabolic and body composition parameters, including waist circumference, body mass index and HOMA-IR, as well as aminotransferase levels and HCV viraemia. F 2 -isoprostane levels were inversely associated with use of antioxidant vitamins or minerals and CD4%. In multivariate analyses, however, only homocysteine level, waist circumference, HCV viraemia and AST level remained significantly associated with this measure of oxidant stress.
In a cross-sectional study of 120 patients in an HIV clinic, Hulgan et al. [17] found that 23% of patients had F 2 -isoprostane levels above what they considered to be the upper limit of normal (41 pg/ml). Using the same assay and criterion, 78% of the women in our study had increased levels. This discrepancy is probably related in part to well established sex differences in this marker of oxidative stress; in the general population, women have significantly higher plasma levels of F 2 -isoprostanes than men [18] . Only 13% of the patients in the initial study by Hulgan et al. [17] were women. Preliminary results of a larger cross-sectional follow-up study by the same group found that female sex was associated with higher levels of F 2 -isoprostanes [19] . The clinical implications of these apparent sexrelated differences are uncertain.
In their initial report, Hulgan et al. [17] found that F 2 -isoprostane concentrations were lower in patients using efavirenz and inversely associated with HIV RNA level. In their follow-up study, use of a non-NRTI (in particular nevirapine) was associated with lower F 2 -isoprostane concentrations [19] . Other factors associated with oxidant stress in the second study were female sex, greater body mass index and heavy smoking. In the present study, we extend their findings by inclusion of additional metabolic, body composition and liverrelated covariates, some of which were positively associated with log F 2 -isoprostane concentration.
The positive association between homocysteine level and oxidant stress, assessed by F 2 -isoprostane concentrations, is consistent with data from the general population [11] . Although homocysteine has been considered to be an independent risk factor for coronary heart disease, lowering of homocysteine through folate supplementation has not had an effect on secondary prevention of myocardial infarction [20, 21] . Whether lowering of homocysteine through folate supplementation could reduce oxidant stress and consequently the incidence of other conditions associated with increased oxidant stress is speculative at this time. Similarly, although our finding of an inverse relationship between antioxidant vitamin or mineral use and oxidative stress is intriguing, it is not clear if use of these supplements is of clinical benefit.
The presence of HCV viraemia and AST level was independently positively associated with oxidant stress in this study. Given the high prevalence of obesity in our study population, AST level might be a marker of non-alcoholic fatty liver disease. Oxidant stress has been postulated to play a role in the pathogenesis of non-alcoholic fatty liver disease, making the association between AST and F 2 -isoprostane levels biologically plausible [22] . It is also conceivable that oxidant stress might contribute to the pathogenesis of HCV-related liver disease. Because liver biopsy data were not available, we were unable to assess definitively whether stage of liver disease was associated with oxidant stress. Among women with HCV infection, however, FIB-4, a validated non-invasive marker of hepatic fibrosis [16] was associated positively with F 2 -isoprostane concentration, suggesting that more advanced fibrosis was associated with greater oxidant stress. Given recent associations between HCV infection and atherosclerotic burden [23] , further studies are warranted to determine if oxidant stress might be mediating this relationship.
Our study has several noteworthy strengths and limitations. This is the largest study of F 2 -isoprostanes in HIV-infected patients and focuses on an underrepresented population of women of predominantly African-American and Latino backgrounds. In the general population, African-American men and women have lower circulating F 2 -isoprostanes relative to individuals who are White and of other races [18] . Although we did not find a statistically significant association between race/ethnicity and F 2 -isoprostanes in this study, we could not rule out the presence of modestly lower levels in individuals who are Black. The metabolic and anthropometric data collected in this study enabled us to explore novel associations. Because of the cross-sectional design, however, we are unable to assess the temporal and potentially causal relationships between oxidant stress and the covariates under study. In addition, the high prevalence of both obesity and diabetes in our study might limit the generalizability to other populations of HIVinfected women. The lack of data on HIV-uninfected controls makes it impossible to determine if plasma F 2 -isoprostane concentrations were increased in HIVinfected women relative to HIV-uninfected women.
In summary, in this cross-sectional study of HIVinfected women, oxidant stress assessed by plasma F 2 -isoprostane concentration was positively associated with waist circumference, HCV viraemia, homocysteine level and AST level. The clinical significance of an increased marker of in vivo oxidant stress is uncertain and requires further study.
